SEC Form 4 · accession 0001140361-17-002734
Opus Genetics, Inc. · IRD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Lisa Nolan
Officer — Chief Business Officer
Period of report
Jan 20, 2017
Accepted (ET)
Jan 24, 2017 · 5:45 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001228627
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $0.184 | Jan 20, 2017 | A | 315,000 | A | — | Jan 20, 2027 | Common Stock | 315,000 | 315,000 | D |
| Restricted Stock UnitsF2,F3 | — | Jan 20, 2017 | A | 65,000 | A | — | — | Common Stock | 65,000 | 65,000 | D |
Explanation of responses
- F1One quarter of the option vests and becomes exercisable on January 20, 2018, and, thereafter, 1/36th of the remaining option vests in equal installments on the first business day of each month until fully vested.
- F2Each restricted stock unit represents a contingent right to receive one share of common stock.
- F3The restricted stock units vest in four equal annual installments on the last business day in February, beginning February 28, 2018.